Vaccines that partially mimic SARS-CoV-2’s structure may elicit very high immune response.

An American biotechnology company announces interim positive results of a COVID-19 vaccine.

Johnson and Johnson’s COVID-19 elicited strong immune responses.

Celltrion announced positive preliminary results from Phase 1 clinical trial.

A newly published study on the prevalence of the novel coronavirus in Spain found that only 5% of the country’s population has developed antibodies, providing proof that herd immunity to COVID-19 may not be achieved.